587 results about "Thrombin" patented technology

The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V):

or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R³, R⁴, R⁶, R¹¹, X¹, X², and X³ are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

A system/analyzer-unit and method/platform—using information obtained from at least one, adapted for a plurality of, magnetoelastic sensor elements in contact with one or more samples comprising blood from a patient—for automatically quantifying one or more parameters of the patient's blood. Information obtained from emissions measured from each of the sensor elements is uniquely processed to determine a quantification about the patient's blood, such as, quantifying platelet aggregation to determine platelet contribution toward clot formation; quantifying fibrin network contribution toward clot formation; quantifying platelet-fibrin clot interactions; quantifying kinetics of thrombin clot generation; quantifying platelet-fibrin clot strength; and so on. Structural aspects of the analyzer-unit include: a cartridge having at least one bay within which a sensor element is positioned; each bay in fluid communication with both (a) an entry port for injecting a first blood sample composed of blood taken from the patient (human or other mammal), and (b) a gas vent through which air displaced by injecting the first blood sample into the bay.

A method of preparing a collagen sponge comprises mixing air into a collagen gel, so as to obtain a collagen foam which is dried. From the dried product thereby obtained, collagen sponge is obtained by isolating parts of sponge with a chamber diameter of more than 0.75 mm and less than 4 mm, or parts with an average chamber diagonal dimension of 3 mm. The collagen sponge may be used as a material for sealing wounds, possibly with a coating comprising a fibrin glue, such as a combination of fibrinogen, thrombin and aprotinin. A device for extracting a part of a collagen foam and for degenerating another part of the collagen foam to a collagen gel is disclosed. An elongated collagen sponge having a through-going hole or bore and a flexible wall may be used for re-establishing walls in a mammalian gastrointestinal funnel or trachea system.

The invention relates to dabigatran ester derivatives as shown in a constitutional formula I, pharmaceutically acceptable nontoxic salts thereof, medical composite containing the compounds as active components, and application of thrombin inhibitor of the compounds and medical composites, wherein R1 represents H or C1 to C5 alkyl; R2 represents H, or C1 to C3 alkyl; and R3 represents C1 to C8 alkyl or substituted alkyl.

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.

The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the NCca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and/or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and/or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.

The invention relates to a manufacturing method and application of an electrochemiluminescence sensor for detecting thrombin. Ruthenium bipyridine with active group is modified to the gold nanoparticle surface to form an electrochemiluminescence nanoparticle probe, which plays the role of amplifying electrochemiluminescence, and the upper part DNA single strand is modified on the working electrode surface to constitute an electrochemiluminescence sensor. The target analyte of thrombin is subjected to reaction with partial DNA double strands and then with DNA polymerase, Nb.BbvCI nicking enzyme and partial DNA single strand to obtain DNA hybrid solution which is added into the sensor, so as to increase electrochemiluminescence nanoparticle probes on the electrode surface and further lead to an enhanced electrochemiluminescence signal, and accordingly thrombin determination is realized. The inventive sensor has high selectivity and detection sensitivity.

The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue.

The invention discloses a preparation method for a hemostatic material, an absorbable carrier material prepared by an electrospinning technology or a combination of the absorbable carrier material and a blood coagulation factor film-shaped material prepared by the electrospinning technology, wherein blood coagulation factors are fibrinogen and thrombin from human or animal blood. The superfine fibre prepared by the electrospinning technology has the advantages that the specific surface area of the reticulate structure of the hemostatic material is increased, and the mutual fusion action between the reticulate structure and tissues is promoted. The hemostatic material is good in biocompatibility, more remarkable in hemostatic effect and convenient to use, and can be used for hemostasis in trauma treatment and clinical operations.

A haemostatic kit to be used as a medical device provides for a containment unit and a haemostatic agent in said containment unit, said haemostatic agent occupying less than 90% of the volume of the containment unit. This allows for facile and consequently sterile preparation of, for instance, a gelatin paste for use in haemostatis when combined with saline, thrombin or another agent to assist in haemostatis.

The present invention discloses one kind of injected bone repairing material and its preparation and application. The injected bone repairing material consists of solution I and solution II, the solution I is the mixture of platelet rich plasma (PRP) and 80-100 mg/ml concentration fibrinogen solution in the ratio of 1 to 3-6; and the solution II is solution mixture of calcium chloride in 40 mmol/ml concentration and thrombin in 400-1000 U/ml concentration. When the injected bone repairing material is used, solution I and solution II in the volume ratio of 1-9 are sucked with two syringes and injected into body to form gel with high adhesive force, with PRP accounting for 10-30 vol%. The injected bone repairing material is used in preparing implant for treating bone defect and bone nonunion and promoting fracture healing.

The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention.

A new oral IR formulation in solid form for a low molecular weight thrombin inhibitor having pH dependant dissolution, characterized in that the formulation comprises a filler or a combination of fillers having disintegrant properties in an amount higher than 35% w/w of the formulation.

The invention relates to antibacterial-hemostatic material with a non-woven fabric fiber fabric structure and a production method of the antibacterial-hemostatic material and belongs to the technical field of biomedical materials. The antibacterial-hemostatic material is characterized in that aliphatic polyester is dissolved into solvent, an electrospun fibrous membrane is produced through static spinning, chitosan is loaded on the surface of the electrospun fibrous membrane, thrombin is further loaded on the surface of the electrospun fibrous membrane, and the antibacterial-hemostatic material is produced. The material features of the aliphatic polyester and the chitosan are utilized, the structure features such as high porosity and high specific surface area of the formed electrospun fibrous membrane are utilized, stable loading of the thrombin is performed by the crosslinking action of the chitosan and glutaraldehyde, and the antibacterial-hemostatic material with the non-woven fabric fiber fabric structure is formed. The antibacterial-hemostatic material has the advantages that the material is good in antibacterial and hemostatic effects, the antibacterial and hemostatic effects of the material are obviously better than those of commercially available gelatin sponge, the material is good in mechanical performance, easy to store and convenient to remove after being used, the production method of the material is simple to operate and capable of reducing raw material use amount, and the material is applicable to fields such as surgery and trauma first-aid.

There is provided a compound of formula I wherein R, R<1>, R<2>, Y and R<3 >have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

The invention discloses a preparation process for extracting human fibrinogens from waste for extracting cryoprecipitated blood coagulation factor VIII. The preparation process is characterized by comprising the steps of cryoprecipitation dissolution, 2% aluminium hydroxide gel absorption, ion strength adjustment, series connection filtering, S/D viral inactivation, ion-exchange chromatography, EDTA Ca2+ removal, glycine precipitation, primary low-temperature ethanol precipitation, AT-III thrombin inhibition, secondary low-temperature ethanol precipitation, nanofilm filtering and dry-heat inactivation. For ensuring the safety, a nanofilm ia added to filter virus except S/D and dry-heat inactivation. By means of an added AT-III inactivated thrombin and EDTA Ca2+ removal process, fibrinogen in the production process is effectively prevented from being activated into fibrous protein. The glycine precipitation is utilized to remove fibrous protein monomers and polymers in products so as obtain high-purity human fibrinogen. The preparation products are safe and reliable, redissolution time is short, the clinic first-aid demand is met, and meanwhile the preparation process has important significance on indirect saving of scarce plasma resources.

The invention discloses a functional platelet bionic intelligent carrier and application thereof in anti-ischemic cerebral apoplexy. The bionic carrier is composed of polymer nanoparticles of a platelet membrane coated neuroprotectant ZL006e, a Tat cell-penetrating peptide as well as substrate peptide fragments and fibrinolytic protein conjugates capable of being cut by thrombin. The carrier system has the characteristics of excellent biocompatibility, capacity of effectively prolonging in-vivo cycle time and the like, and is capable of targeting micro-thrombus in lesions of ischemic cerebralapoplexy and releasing thrombolytic drugs. Meanwhile, the exposed Tat cell-penetrating peptide mediated neuroprotectant is capable of increasing blood-brain barrier permeability, the pH serves as an intelligent drug release switch, and the pH-mediated degradation at the lesions is responded, so that the drug is quickly released at lesions of cerebral ischemia, the curative effects are improved tothe greatest degree, and toxic and side effects are reduced.

A method for assessing coagulation in a test sample is provided wherein an activator is added to a test sample in an amount sufficient to trigger a thrombin explosion dependent on propagation phase and amplification pathways but said amount insufficient to result in complete fibrin polymerization, followed by measuring the amount of fibrin polymerization due to the thrombin explosion and assessing the patient's coagulation based on the measurement of the fibrin polymerization. The method also provides a means for detecting defects in the propagation and amplification phases of coagulation.